Inquiry: The Journal of Health Care Organization, Provision, and Financing (Dec 2021)

Medicaid Expansion and Racial/Ethnic Differences in Readmission After Acute Ischemic Stroke

  • Blake T. McGee PhD, MPH, RN,
  • Seiyoun Kim PhD,
  • Dawn M. Aycock PhD, RN, ANP-BC, FAAN, FAHA,
  • Matthew J. Hayat PhD,
  • Karen B. Seagraves PhD, MPH, NEA-BC, FAHA,
  • William S. Custer PhD

DOI
https://doi.org/10.1177/00469580211062438
Journal volume & issue
Vol. 58

Abstract

Read online

To examine whether rates of 30-day readmission after acute ischemic stroke changed differentially between Medicaid expansion and non-expansion states, and whether race/ethnicity moderated this change, we conducted a difference-in-differences analysis using 6 state inpatient databases (AR, FL, GA, MD, NM, and WA) from the Healthcare Cost and Utilization Project. Analysis included all patients aged 19-64 hospitalized in 2012–2015 with a principal diagnosis of ischemic stroke and a primary payer of Medicaid, self-pay, or no charge, who resided in the state where admitted and were discharged alive (N=28 330). No association was detected between Medicaid expansion and readmission overall, but there was evidence of moderation by race/ethnicity. The predicted probability of all-cause readmission among non-Hispanic White patients rose an estimated 2.6 percentage points (or 39%) in expansion states but not in non-expansion states, whereas it increased by 1.5 percentage points (or 23%) for non-White and Hispanic patients in non- expansion states. Therefore, Medicaid expansion was associated with a rise in readmission probability that was 4.0 percentage points higher for non-Hispanic Whites compared to other racial/ethnic groups, after adjustment for covariates. Similar trends were observed when unplanned and potentially preventable readmissions were isolated. Among low-income stroke survivors, we found evidence that 2 years of Medicaid expansion promoted rehospitalization, but only for White patients. Future studies should verify these findings over a longer follow-up period.